PMC:7274950 / 10833-11760
Annnotations
LitCovid-PMC-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T136 | 109-125 | UBERON:0005409 | denotes | gastrointestinal |
T137 | 155-159 | UBERON:0000104 | denotes | life |
T138 | 168-174 | UBERON:0001969 | denotes | plasma |
T139 | 180-183 | PR:Q9SMQ6 | denotes | Gb3 |
T140 | 201-204 | PR:Q9SMQ6 | denotes | Gb3 |
T141 | 205-215 | GO:0016234 | denotes | inclusions |
T142 | 221-226 | UBERON:0002113;CL:1000497 | denotes | renal |
T143 | 227-232 | CL:1000497 | denotes | cells |
T144 | 269-278 | CL:0000653 | denotes | podocytes |
T145 | 411-416 | UBERON:0000062 | denotes | organ |
T146 | 653-661 | SP_7 | denotes | COVID-19 |
T147 | 829-837 | SP_7 | denotes | COVID-19 |
T148 | 846-854 | SP_7 | denotes | COVID-19 |
T9604 | 109-125 | UBERON:0005409 | denotes | gastrointestinal |
T14185 | 155-159 | UBERON:0000104 | denotes | life |
T5065 | 168-174 | UBERON:0001969 | denotes | plasma |
T88556 | 180-183 | PR:Q9SMQ6 | denotes | Gb3 |
T99402 | 201-204 | PR:Q9SMQ6 | denotes | Gb3 |
T63298 | 205-215 | GO:0016234 | denotes | inclusions |
T77613 | 221-226 | UBERON:0002113;CL:1000497 | denotes | renal |
T37944 | 227-232 | CL:1000497 | denotes | cells |
T76245 | 269-278 | CL:0000653 | denotes | podocytes |
T26927 | 411-416 | UBERON:0000062 | denotes | organ |
T25428 | 653-661 | SP_7 | denotes | COVID-19 |
T37112 | 829-837 | SP_7 | denotes | COVID-19 |
T85471 | 846-854 | SP_7 | denotes | COVID-19 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
277 | 335-343 | Species | denotes | patients | Tax:9606 |
278 | 175-183 | Chemical | denotes | lyso-Gb3 | MESH:C063288 |
279 | 55-68 | Disease | denotes | Fabry disease | MESH:D000795 |
280 | 88-104 | Disease | denotes | neuropathic pain | MESH:D009437 |
281 | 109-134 | Disease | denotes | gastrointestinal symptoms | MESH:D012817 |
286 | 855-863 | Species | denotes | patients | Tax:9606 |
287 | 653-661 | Disease | denotes | COVID-19 | MESH:C000657245 |
288 | 829-837 | Disease | denotes | COVID-19 | MESH:C000657245 |
289 | 846-854 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T53 | 168-174 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T54 | 221-232 | Body_part | denotes | renal cells | http://purl.org/sig/ont/fma/fma86785 |
T55 | 227-232 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
T56 | 411-416 | Body_part | denotes | organ | http://purl.org/sig/ont/fma/fma67498 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T28 | 411-416 | Body_part | denotes | organ | http://purl.obolibrary.org/obo/UBERON_0000062 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T61 | 55-68 | Disease | denotes | Fabry disease | http://purl.obolibrary.org/obo/MONDO_0010526 |
T62 | 653-661 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T63 | 829-837 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T64 | 846-854 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T119 | 19-22 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T120 | 23-24 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T121 | 168-174 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
T122 | 227-232 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
T123 | 239-240 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T124 | 310-314 | http://purl.obolibrary.org/obo/UBERON_0003101 | denotes | male |
T125 | 310-314 | http://www.ebi.ac.uk/efo/EFO_0000970 | denotes | male |
T126 | 411-416 | http://purl.obolibrary.org/obo/UBERON_0003103 | denotes | organ |
T127 | 424-427 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T128 | 463-464 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T27 | 180-183 | Chemical | denotes | Gb3 | http://purl.obolibrary.org/obo/CHEBI_18313 |
T28 | 201-204 | Chemical | denotes | Gb3 | http://purl.obolibrary.org/obo/CHEBI_18313 |
T29 | 310-314 | Chemical | denotes | male | http://purl.obolibrary.org/obo/CHEBI_30780 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T38 | 100-104 | Phenotype | denotes | pain | http://purl.obolibrary.org/obo/HP_0012531 |
LitCovid-PD-GlycoEpitope
Id | Subject | Object | Predicate | Lexical cue | glyco_epitope_db_id |
---|---|---|---|---|---|
T5 | 180-183 | GlycoEpitope | denotes | Gb3 | http://www.glycoepitope.jp/epitopes/EP0071 |
T6 | 201-204 | GlycoEpitope | denotes | Gb3 | http://www.glycoepitope.jp/epitopes/EP0071 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T78 | 0-14 | Sentence | denotes | 1 Conclusions |
T79 | 15-279 | Sentence | denotes | ERT has a beneficial clinical impact in Fabry disease, as it can relieve neuropathic pain and gastrointestinal symptoms, improve quality of life, reduce plasma lyso-Gb3 levels and clear Gb3 inclusions from renal cells, with a dose-dependent mechanism in podocytes. |
T80 | 280-438 | Sentence | denotes | Evidence, mainly derived from male studies, shows that patients may benefit from early treatment initiation, before major clinical organ damage has developed. |
T81 | 439-566 | Sentence | denotes | After ERT interruption, a recommencement of therapy does not fully reverse clinical decline resulting from the discontinuation. |
T82 | 567-755 | Sentence | denotes | Home-therapy seems to be the most efficient way to maintain therapy access during the COVID-19 pandemic when possible and correct use of personal protective equipment should be guaranteed. |
T83 | 756-927 | Sentence | denotes | If home-therapy is not available, safe locations and plans that separate COVID-19 and non-COVID-19 patients should be carefully prepared in hospitals and infusion centers. |